Clinical Trial Update: Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib with or without irinotecan in locally recurrent or metastatic squamous cell carcinoma of the head and neck; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Head and Neck
• Squamous Cell Carcinoma of the Hypopharynx
• Squamous Cell Carcinoma of the Larynx
• Squamous Cell Carcinoma of the Lip and Oral Cavity
• Squamous Cell Carcinoma of the Nasopharynx
• Squamous Cell Carcinoma of the Oropharynx
• Squamous Cell Carcinoma of the Paranasal Sinuses and Nasal Cavity
• Tongue Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx | Phase 2 | Status: COMPLETED | Results posted: 2012-12-27